What is Zenas BioPharma, Inc. Common Stock?
, a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.90B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 2153,768 shares $3.1M |
| 9-12months | 0 | 7202,845 shares $3.7M |